Ryan Lynch sold $4,296 of CBIO
See Remarks at CRESCENT BIOPHARMA, INC.. 240 shares at an average of $17.90, traded Sep 16, 2026, filed Sep 18, 2026.
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- 0Share of holdings soldSold 1.7% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-062709, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -240 | $17.90 | $4,296 | 13,631 | 24 d ago |
Related signals
Other insiders at CRESCENT BIOPHARMA, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | CRESCENT BIOPHARMA, INC. | Barbara Harlin Bispham See Remarks | $11k 620 shares | -3% | |
| 31Weak | CRESCENT BIOPHARMA, INC. | Joshua T Brumm Chief Executive Officer | $160k 9,447 shares | -3% | |
| 23Weak | CRESCENT BIOPHARMA, INC. | Jonathan McNeill President and COO | $77k 4,570 shares | -3% | |
| 17Weak | CRESCENT BIOPHARMA, INC. | Richard William Scalzo Chief Financial Officer | $10k 568 shares | -3% | |
| 10Weak | CRESCENT BIOPHARMA, INC. | Ellie Eunkyung Im Chief Medical Officer | $11k 623 shares | -3% | |
| 10Weak | CRESCENT BIOPHARMA, INC. | Jan Pinkas Chief Scientific Officer | $12k 658 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.